[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100565643":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":32,"responsibleParty":47,"collaborators":20,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":20,"eligibilityCriteria":57,"healthyVolunteers":53,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":20,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":72,"overallStatus":35,"whyStopped":20,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":87},{"fullName":5,"class":6},"Tata Memorial Hospital","OTHER_GOV",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"SFRT arm","EXPERIMENTAL","This is a single arm phase II study. All patients will receive the planned intervention ie. spatially fractionated radiation therapy using rapid rod technique.",[13],"Radiation: Spatially fractionated radiation therapy",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"RADIATION","Spatially fractionated radiation therapy","Spatially fractionated\" radiation therapy (SFRT) enables delivery of high-dose radiation to discrete sub-volumes inside a tumour target while restricting the remainder of the target to a safer lower dose. This technique results in generation of intentionally heterogeneous dose distribution with spatial areas of \"hot\" and \"cold\" spots within the tumour, thereby sparing nearby organs at risk.",[9],null,[22,28],{"name":23,"role":24,"phone":25,"phoneExt":26,"email":27},"Supriya Chopra, MD","CONTACT","022-68735000","5113","supriyasastri@gmail.com",{"name":29,"role":24,"phone":30,"phoneExt":20,"email":31},"Ankita Gupta, MD","9592750011","ankita19.gupta.ag@gmail.com",[33],{"facility":34,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":20},"ACTREC Tata Memorial Centre","RECRUITING","Navi Mumbai","Maharashtra","410210","India","IN",{"type":42,"coordinates":43},"Point",[44,45],73.01582,19.03681,{"lat":45,"lon":44},{"type":48,"investigatorFullName":49,"investigatorTitle":50,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"PRINCIPAL_INVESTIGATOR","Supriya Sastri (chopra)","Dr Supriya Sastri","100565643","spatially-fractionated-radiation-treatment-for-gynaecological-cancers-100565643",false,"NCT06644846","Spatially Fractionated Radiation Treatment for Gynaecological Cancers","A Prospective Study of Spatially Fractionated Radiation Treatment Using Rapid Rod Technique for Gynaecological Cancers","Inclusion Criteria:\n\n1. Patients with cervical cancer post EBRT, with expected suboptimal brachytherapy dose coverage due to-\n\n   1. Aberrant uterine or pelvic anatomy leading to difficulty in localization of the cervical OS or negotiation of the uterine canal accurately by two independent clinicians in up to two procedures.\n   2. Large residual disease at the time of brachytherapy with anticipated suboptimal target coverage either determined in clinic based on pre-brachytherapy imaging or at dose planning (e.g. figure 2).\n   3. Very narrow vaginal canal not accommodating even the smallest intracavitary or vaginal cylinder applicators.\n2. Patients with inoperable endometrial cancer not suitable for anaesthesia or have anticipated suboptimal coverage of target volume at brachytherapy as identified on pre-brachytherapy imaging obtained after EBRT.\n3. Patients with large pelvic recurrences after surgery and\u002For (chemo) radiation, not amenable to surgical salvage or brachytherapy after salvage EBRT due to reasons specified in item 1.\n4. Patients with contraindications to anaesthesia for brachytherapy with sufficient risk of on-table or post procedure adverse events.\n\nExclusion Criteria:\n\n1. Any pre-existing fistula in bladder or rectum.\n2. Pelvic prosthesis.\n3. Refusal to provide consent.","FEMALE","18 Years","70 Years",{"count":62,"type":63},20,"ESTIMATED","INTERVENTIONAL",[66],"NA","This is a prospective study to evaluate in-field disease control, survival and late toxicity in patients with cervical cancer or pelvic recurrence treated with spatially fractionated RT.\n\nThe study will include patients with primary cervical cancer or pelvic recurrence not suitable for brachytherapy in view of anticipated or actual suboptimal target coverage due to aberrant anatomy or large residual disease at the time of brachytherapy.",[69,70,71],"Cervical Cancer","Gynecologic Cancer","Recurrent Cancer",[73,74,75,76,77],"Cervical cancer","Cancer","Recurrence","Spatially fractionated radiotherapy","Rapid rod","2026-02-18",{"date":80,"type":81},"2026-02-20","ACTUAL",{"date":83,"type":81},"2024-10-04",{"date":85,"type":63},"2029-02-28",{"name":5,"class":6},1]